Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Neurofibromatosis Type 1 - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report delivers in-depth insights into the ...

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin. Basal ...

Please provide your email address to receive an email when new articles are posted on . Severe auditory dysfunction was a common neurobiological feature of neurofibromatosis type 1, according to ...

EAGAN, Minn., Jan. 12, 2021 /PRNewswire/ -- Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture ...

Other than surgery and medications, including opioids, there are few options for treating pain symptoms, which affect more than half of all patients with neurofibromatosis type 1. Researchers recently ...

Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

Although brain tumors have largely remained resistant to immunotherapy, a new study has shown that a slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 (NF1) may be ...

Neurofibromatosis type 1 (NF1) is a prevalent genetic disorder caused by germline mutations in the NF1 gene, leading to dysregulation of RAS signalling and predisposing affected individuals to diverse ...

Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis and is also one of the most common inherited neurological disorders, affecting about 1 in 3,000 people ...

The Key Neurofibromatosis Type 1 Companies in the market include - AstraZeneca and Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical, NFlection Therapeutics, and ...